«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《环球中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:

第8卷

期数:

2015年09期

页码:

1145-1144

栏目:

综述

出版日期:

2015-09-06

文章信息/Info

Title:

Review on molecular and cellular mechanism researches of emodin for treating kidney disease

作者:

齐振强; 胡洪贞; 王祥生; 李伟

250000 济南,山东中医药大学第一临床学院

Author(s):

QI Zhen-qiang;  HU Hong-zhen;  WANG Xiang-sheng;  et al.

First school of clinical medicine, Shandong University of Traditional Chinese Medicine, Jinan 250000, China

关键词:

大黄素;  肾脏疾病;  分子细胞;  机制

Keywords:

Emodin;  Kidney disease;  Molecular and cellular;  Mechanism

分类号:

R285

DOI:

10.3969/j.issn.1674-1749.2015.09.033

文献标志码:

A

摘要:

大黄素是中药大黄的有效单体成分之一,具有多种功效。在治疗肾脏疾病方面,大黄素具有抗增殖,减少细胞外基质集聚,抗肾间质纤维化,抗炎及免疫抑制等多种作用,其作用主要是通过对肾脏细胞、细胞因子、生长因子、细胞外基质等多方面发挥效能而实现的。最新的分子细胞机制研究主要围绕细胞及细胞因子展开,目前已发现大黄素可通过作用于转化生长因子-β、结缔组织生长因子、单核细胞趋化蛋白-1、血小板反应蛋白-1等发挥其抗增殖、抗纤维化的作用,从而达到治疗肾脏疾病的目的。

Abstract:

Emodin is an important monomer from traditional Chinese medicine radix et rhizoma rhei, which has many functions. In the treatment of kidney disease, emodin has anti-proliferation, inhibition of excessive deposition of glomeruli extracellular matrix, anti-renal interstitial fibrosis, anti-inflammatory and immune suppressive functions, which are realized through regulating kidney cells, cytokines, growth factors, and extracellular matrix, etc. Latest studies on molecular and cellular mechanisms of emodin mainly involve cells and cytokines, like TGF-β, CTGF, MCP-1, and TSP-1 to achieve the purpose of treating kidney diseases.

参考文献/References:

［1］ Liu H,Gao Y.Research progression in molecular mechanism of the pharmacol- ogical actions of emodin[J]. Chin Pharnacol Bull,2009, 25(12):1552-1555.
［2] Wang W,Koka V,Lan HY. Transforming growth factor-beta and Smad sign- alling in Kidney disease[J]. Nephrology(Carlton), 2005, 10(1):48-56.
［3] 杨君,秦英,赵斐,等. 大黄酸及大黄素对人肾小管上皮细胞增殖及TGF-β1启动子活性的调控作用[J].上海中医药大学学报,2013,27(5):70-72.
［4] 朱凌波.氟伐他汀和大黄素对早期糖尿病肾病患者TGF-β1水平的影响[J].黑龙江中医药,2009,(9):52-53.
［5] 魏建波,刘琴,钟瑜,等. 大黄素对大鼠肾间质纤维化干预作用的实验研究[J].浙江中西医结合杂志,2013,(5):337-341.
［6] Gupta S,Clarkson MR,Duggan J, et al.Connecctive tissue growth factor:pot- ential role in glomerulosclerosis and tubulointerstitial fibrosis[J]. Kidney Int, 2000,(58):1389-1399.
［7］ 陶松青,何劲松. 大黄素对糖尿病大鼠肾脏结缔组织生长因子表达的影响[J].现代中西医结合杂志,2010,19(24):3023-3027.
［8] Klahr S, Purkerson MI. The pathophysiology of obstructive nephropathy:The role of vasoactive compounds in the hemodnamic and abonomalities of the obst- ructed kidney[J]. Am J Kidney Dis,1994,(23):219.
［9] I-hm CG, Park JK, Hong SP, et al. Circulating factors in sera or peripheral blood mononuclear cells in patients with membranous nephropathy or diabetic nep-hropathy[J]. J Korean Med Sci, 1997,(12):539-544.
［10] Akahoshi T, Kobayashi N, Hosaka S, et al. In-vivo induction of monocyte che- motactic and activating factor in patients with chronic renal failure[J]. Nephrol Dial Transplant,1995, 10(12):2244-2249.
［11] 何劲松,曹东维. 大黄素对糖尿病大鼠肾组织单核细胞趋化蛋白-1表达的影响[J]. 中国生化药物杂志, 2012, 33(6):795-797.
［12] Hugo C,Daniel C. Thrombospondin in renal disease[J]. Nephron Exp Nephrol,2009,111( 3):61-66.
［13] 赵小萍,曾嵘,王俭勤,等.大黄素对高糖介导的大鼠NRK52E TSP1和TGF-β1表达的影响[J].中国民族民间医药,2009,18(14):1-3.
［14] 刘友霞,刘毅,曹铭锋,等,大黄素对高糖环境下系膜细胞收缩功能的影响[J].山东大学学报(医学版),2010, 48(9):14-18.
［15] 李学娟,陈泽彬,魏红,等.大黄素对高糖培养的GMC增殖、FN表达及p38M- APK的影响[J].中国药理学通报,2014, 30(2):233-237.
［16] Kida Y, Asahina K, Teraoka H, et al.Twist relates to tubular epithelial-mesenchymal transition and interstitial fibrogenesis in the obstructed kidney[J].J Histochem Cytochem, 2007, 55(7):661-673.
［17] 金国华,秦晓华,秦艳东,等.TGF-β1/Smad信号通路在大黄素干预人肾小管上皮细胞转分化中的作用[J].实用医学杂志,2012,28(1):36-38.
［18] 金国华,秦晓华,秦艳东,等.大黄素对人白蛋白诱导人肾小管上皮细胞转分化的影响[J].天津医药,2013,41(1):26-28.
［19] 陈廷芳,陈明,秦建华.转化生长因子β1/整合素连接激酶信号通路在大鼠肾小管上皮细胞转分化中的作用及大黄素对其的干预效应[J]. 中西医结合学报,2009,7(1): 59-64.
［20] 杨亚珍,朱晓玲,王永钧,等.大黄素对脂多糖所致肾脏炎症的抑制作用[J]. 中国医药导报, 2013, 10(36):8-11.
［21] Zhu XL,Wang YJ, Yang Y Z, et al.O'Byrne KT.Suppression of lipopolysacchari- de-induced upregulation of toll-like receptor 4 by emodin in mouse proximal tubular epithelial cells[J].Mol Med Rep, 2012,6(3):493-500.
［22] 朱晓玲,王永钧,杨亚珍.大黄素对TLR4基因介导的肾小管上皮细胞LPS信号转导的机理研究[C]//第十一届全国中西医结合肾脏病学术会议论文汇编,重庆, 2010.
［23] Liu L, Zou J, Liu X,et al.Inhibition of ATP-induced macrophage death by emodin via antagonizing P2X7 receptor[J].Eur J Pharmacol,2010,640(1-3):15-19.
［24] 朱晓玲,王永钧,张华琴,等.积雪草甙合人黄素对TNF-α诱导肾小管上皮细胞C3上调的干预作用[J].中国中医药科技,2010,17(1):32-23.
［25] 乔振奎,张卓然,田立志,等.大黄素对犬自体肾移植缺血再灌注损伤的保护作用研究[J]. 现代药物与临床,2014,2(29):131-134.
［26] 李冬梅,刘巍. 大黄素对肾纤维化大鼠肾组织MMP -9表达的影响[J]. 中国中医药现代远程教育,2014, 12(10):160-161.
［27] 李冬梅,孙禄,刘巍,等.大黄素对肾纤维化大鼠肾组织中基质金属蛋白酶组织抑制物-1表达的影响[J]. 齐齐哈尔医学院学报,2010,(17):1689-1690.
［28] Yang J, Zeng Z, Wu T, et al.Emodin attenuates high glucose-in- duced TGF-β1 and fibronectin expression in mesangial cells through inhibition of NF-κB pathway[J].Exp Cell Res,2013, 319(20):3182-3189.
［29] National Toxicology Program. NTP toxicology and carcinogenesis studies of emodin(CAS NO. 518-82-1)feed atudies in F344/N rats and B6C3F1 mice [J]. Natl Toxicol Program Tech Rep Ser, 2001,493:1-278.
［30] 魏群利,郭禹,印晓星,等. 大黄素干预高糖培养大鼠肾小球系膜细胞的凋亡[J]. 中国组织工程研究,2012, 16(31):5817-5822.
［31] 李奇,王伽伯,方芳,等.大剂量何首乌醇提物引发大鼠多脏器损害[J].环球中医药,2013,6(1):1-7.
［32] 雷荣辉,王青秀,颜贤忠,等.利用～1H-NMR技术研究大黄素染毒后大鼠内源性代谢物的改变[J].药物评价研究,2015,38(1):29-35.
［33] 关翠雯,金晶,朱少华,等.大黄素诱导人肾上皮HK-2细胞凋亡及内质网应激的介导作用[J]. 中草药,2013,6(12):1621-1627.

相似文献/References:

备注/Memo

备注/Memo:

-

常用功能

更新日期/Last Update: 1900-01-01